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INTRODUCTION
Calcium channel blockers (CCBs), also known as calci-
um antagonists, are commonly prescribed drugs for the 
treatment of various conditions of the heart and blood 
vessels, such as hypertension, angina pectoris, supra-
ventricular dysrhythmias, after myocardial infarction 
and in migraine prophylaxis. They support vasodilator 
activity and reduce blood pressure by decreasing cal-
cium influx into vascular smooth muscle cells (Stella et 
al., 2007; Lemke and Williams, 2008; Sweetman, 2009; 
Beale and Block, 2011; Mofat et al., 2011).
Most CCBs, with the exception of amlodipine (64-
90%) and nifedipine (45-70%), have variable oral bio-
availability because of extensive first-pass metabolism. 
Their half-life is relatively short – usually shorter than 
12 hours, with the exception of amlodipine which, al-
though extensively metabolized, has half-life of 35-50 
hours. According to the available literature data, CCBs 
have a dual route of elimination, renal and fecal. The 
lowest values for renal and highest values for fecal 
elimination of CCBs was found for diltiazem, while 
for nimodipine renal elimination is the major route of 
elimination. CCBs combine well with antihypertensive 
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drugs that block the rennin-angiotensin system, ACE 
inhibitors and angiotensin receptor blockers (Stella et 
al., 2007; Lemke and Williams, 2008; Sweetman, 2009; 
Beale and Block, 2011; Mofat et al., 2011).
According to their structural and functional dis-
tinctions, CCBs can be subdivided into three groups: 
dihydropyridine derivatives (amlodipine, felodipine, is-
radipine, lacidipine, lercanidipine, nicardipine, nifedip-
ine and nisoldipine), phenylalkylamine (verapamil) and 
benzothiazepine derivatives (diltiazem) (Lemke and 
Williams, 2008). Dihydropyridine derivatives have pro-
nounced peripheral vasodilator properties; their eflex 
cardiac stimulation overcomes direct cardiac effects; 
verapamil and diltiazem are vasodilators, but with more 
noticeable cardiac effects, including reduced heart rate 
(Stella et al., 2007; Lemke and Williams, 2008; Sweet-
man, 2009; Beale and Block, 2011; Mofat et al., 2011). 
The clinical success of drugs mostly depends on 
their absorption, distribution, metabolism or route of 
elimination (Di and Kernsy, 2003). Lipophilicity is one 
of the most important molecular properties that influ-
ences these values, but a number of other molecular 
properties, such as molecular weight (Mw), molecular 
volume (Vol), polar surface area (PSA) and solubility 
data (logS), also play an important role in drug absorp-
tion, penetration into tissues, degree of distribution, 
degree of plasma protein binding and route of elimina-
tion (Hartman and Schmitt, 2004; Remko et al.,, 2006; 
Remko, 2007; Zhao, 2001). According to the available 
literature, a number of authors investigated antihyper-
tensive drugs including those belonging to the CCB 
group, their design and synthesis (Christiaans et al., 
1993; Kalavagunta et al., 2014), as well as pharmaco-
kinetics, pharmacodynamics and efficacy (Pozo and 
Baeyens, 1986; Sepehr-Ara et al., 2011; Ian Whyte et al., 
2012; Mayama, 2014). Their acidity, lipophilicity, solu-
bility or absorption were evaluated together with large 
groups of different drugs based on their molecular 
structure with the application of computer programs 
(Remko et al., 2006; Remko, 2007; Zhao, 2001). 
The aim of this study was to compare the differ-
ent molecular properties of nine CCBs (amlodipine, 
felodipine, isradipine, nicardipine, nifedipine, ni-
modipine, nisoldipine, verapamil and diltiazem) and 
their elimination data. 
Fig. 1. The relationship between CCB renal elimination data col-
lected from the literature (A) and predicted (B) using ClogP and 
Mw values. Numbers denote CCBs – calcium channel blockers 
(Table 1).
MATERIALS AND METHODS
The nine CCBs investigated were: amlodipine, felo-
dipine, isradipine, nicardipine, nifedipine, nimodip-
ine, nisoldipine, verapamil and diltiazem.
CCB aqueous solubility data (logS) were cal-
culated using the software Virtual Computational 
Chemistry Laboratory and the software package 
Molinspiration Depiction Software (Molinspiration 
Cheminfirmatics) was used for the calculation of 
electronic descriptors: polar surface area (PSA); con-
stitutional parameter (molecular weight (Mw)); geo-
metric descriptor (volume value (Vol)). Chemdraw 
ultra 12.0 was used for the calculation of lipophilicity 
parameters, ClogP values. All calculated molecular 
descriptors are presented in Table 1. The elimination 
data of the investigated CCBs (Table 1) were obtained 
from the relevant literature (Lemke and Williams, 
2008). Microsoft Excel 2003 and Origin 7.0 PRO (Or-
igin Lab Corporation, USA) were used for statistical 
analysis.
RESULTS
According to the available data from literature, CCBs 
have a dual route of elimination, (renal and fecal) 
and renal elimination has been shown as the major 
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one. The lowest values for renal and highest for fecal 
elimination were found for diltiazem (35% and 65%, 
respectively). For nimodipine, renal elimination is the 
major route of elimination (Table 1). 
The five CCB molecular descriptors (PSA, Mw, 
Vol, logP, logS) were calculated using different soft-
ware packages (Table 1). The correlations between 
CCB elimination data obtained from the relevant 
literature and the calculated molecular descriptors 
(PSA, Mw, Vol, logP, logS) were initially investigated 
using simple linear regression, providing very poor 
correlation with coefficients (R2) of around 0.25. 
In the next stage of the study, the relationships be-
tween CCB renal and fecal elimination data and two 
different CCB molecular descriptors were investigated 
using multiple linear regression (MLR). The relation-
ship between CCB fecal as well as renal elimination 
data and lipophilicity with the application of molecular 
weight or volume data as an additional independent 
variable provided similar correlations, with coefficients 
(R2) around 0.38. The predicted values of CCB renal 
and fecal elimination data are presented in Table 2. 
Finally, all relationships were investigated af-
ter nimodipine exclusion, since it was noticed that 
Table 1. Data of CCBs renal and fecal elimination data collected from relevant literature and calculated molecular descriptors
CCBs Renal el.%* Fecal el.%* PSA Mw Vol ClogP.
1. Amlodipine 60 25 100 409 364 3.43
2. Felodipine 70 10 65 384 323 2.24
3. Isradipine 65 30 104 371 330 3.92
4. Nicardipine 60 35 114 480 437 5.23
5. Nifedipine 70 15 110 346 303 3.13
6. Nimodipine 100 0 120 418 379 4.00
7. Nislodipine 75 12 110 388 353 4.58
8. Verapamil 70 16 64 455 454 4.47
9. Diltiazem 35 65 59 415 378 1.19
(*)CCB values were obtained from Lemke and Williams (2008)
Table 2. CCB renal and fecal elimination data predicted from ClogP and Mw (a) and ClogP and Vol values (b).
CCBs Renal el. %(a) Renal el. %(b) Fecal el. %(a) Fecal el. %(b)
1. Amlodipine 66 67 25 24
2. Felodipine 59 61 31 28
3. Isradipine 76 76 12 12
4. Nicardipine 71 73 23 19
5. Nifedipine 73 72 14 15
6. Nimodipine 69 70 21 21
7. Nislodipine 79 79 9 10
8. Verapamil 68 64 25 30
9. Diltiazem 45 44 48 49
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nimodipine renal elimination is the major elimina-
tion route, without values of fecal elimination data. 
Relatively low correlations (R2 around 0.45) were 
established for the relationships between CCBs pre-
sented in the available literature and the predicted 
fecal elimination data. 
However, for relationships between renal elimi-
nation data collected from the relevant literature and 
those predicted, applying computed lipophilicity de-
scriptor (ClogP) and molecular weight (Mw) or mo-
lecular volume (Vol) as independent variables, higher 
correlations were established.
Eq. 1:
Renal el.pred (%) = 7.995(±2.718)ClogP – 0.175(±0.082)
Mw + 105.907(±30.889)
where n = 8; R2 = 0.658; S.D. = 8.666; F = 4.801;
Eq. 2:
Renal el.pred (%) = 8.108(±2.930)ClogP – 0.136(±0.072)
Vol + 84.467(±23.902)
where n = 8; R2 = 0.619; S.D. = 9.142; F = 4.062.
The better correlation, obtained using MLR 
analysis applying ClogP and Mw as independent 
variables (Eq. 1) is presented in Fig. 1. The estab-
lished correlation can be considered as good, as has 
been proposed previously by Asuero et al. (2006), 
with acceptable P values, due to the limited number 
of compounds. 
The correlation that was found between CCB 
renal elimination data and their in silico molecu-
lar descriptors, the lipophilicity parameter (ClogP) 
and the constitutional parameter (molecular weight 
(Mw)), confirmed descriptor calculation as the high-
throughput screening technique (HTS) for evaluation 
of elimination of the selected compounds. 
DISCUSSION
In this research nine CCBs (amlodipine, felodipine, 
isradipine, nicardipine, nifedipine, nimodipine, nisol-
dipine, verapamil and diltiazem) were studied in order 
to evaluate the correlation between their renal and fecal 
elimination data obtained from relevant literature and 
calculated molecular descriptors. The main aim was 
to establish a high throughput approach using simple 
or multiple linear regression analysis capable of pre-
dicting elimination data of the selected CCBs. Several 
CCB molecular descriptors were calculated using three 
different software packages. All calculated descriptors, 
electronic descriptor – PSA, constitutional parameter 
– Mw, geometric descriptor – Vol, lipophilicity descrip-
tors − ClogP values, as well as aqueous solubility data 
– logS, play an important role in drug absorption, 
distribution, metabolism and route of elimination. 
The molecules with high lipophilicity show a high-
er degree of absorption, better penetration into tissues 
and distribution compared to less lipophilic molecules 
with similar properties. Drug absorption as well as du-
ration of action or efficiency and elimination is highly 
affected by its lipophilicity, solubility, molecular size 
and other molecular properties (Lipinski, 2000; Ghose 
el al. 1999). The weakly lipophilic drugs are mostly 
eliminated by urine, while the highly lipophilic ones 
usually exhibit a high degree of fecal elimination. 
According to the available literature, CCB phar-
macokinetics, pharmacodynamics and efficacy were 
investigated by a number of authors (Pozo and Baey-
ens, 1986; Sepehr-Ara et al., 2011; Ian Whyte et al., 
2012; Mayama, 2014). Also, various authors suggested 
several assays that could be employed in studies of the 
elimination of different drugs (Hellstern et al., 1990; 
Kullak-Ublick and Becker, 2003; Verho et al., 1995; 
Martin et al., 2003). However, most of these meth-
ods have certain limitations and a new approach for a 
fast, reliable and cost-effective evaluation of the CCB 
route of elimination should be developed. Since the 
route and degree of elimination of drugs may affect 
their duration of action and activity, the application 
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of computed molecular descriptors in the prediction 
of drug elimination are of great importance, especially 
for the newly synthesized drugs.
In the present study, the correlations between cal-
culated CCB molecular descriptors and their elimi-
nation data obtained from relevant literature were 
examined. In the first step of the investigation the 
correlations between CCBs elimination data obtained 
from relevant literature and the calculated descrip-
tors were investigated using simple linear regression. 
Fecal elimination data and CCBs molecular descrip-
tors − Vol, Mw and logS, showed very low correlations 
(R2<0.10), while only the electronic descriptor (polar 
surface area, PSA) and lipophilicity descriptor (ClogP) 
provided correlation with coefficients (R2) of around 
0.25. In the next stage of the study, the relationship 
between CCB renal as well as fecal elimination data 
and two different CCB molecular descriptors were in-
vestigated using multiple linear regression. ClogP was 
chosen as the first independent variable since it showed 
the best correlations with CCB elimination data (renal 
as well as fecal), while values of Mw, Vol and logS were 
chosen as possible second independent variables. Val-
ues of electronic descriptor (PSA) couldn’t be used as 
the second independent variable, since in correlation 
with ClogP, R2 was 0.39. The relationship between CCB 
fecal elimination data and lipophilicity with application 
of logS as the second independent variable provided 
very poor correlation (R2 < 0.25). Correlations between 
CCB fecal elimination data and lipophilicity with the 
application of molecular weight or volume data as ad-
ditional independent variables provided the same coef-
ficients (R2 = 0.39), while correlations with R2 = 0.37 
were established for renal elimination data. However, 
among all investigated CCBs, only for nimodipine 
was renal elimination appointed as the major route 
of elimination, without absolute values of fecal elimi-
nation data. Therefore, the investigated relationships 
were recalculated after excluding nimodipine and sig-
nificantly higher correlations were found. The best cor-
relation was established between renal elimination data 
collected from relevant literature and those predicted 
applying the computed ClogP and Mw (R2 = 0.66). 
CONCLUSION
The correlation between nine CCB elimination data 
and five different molecular descriptors were inves-
tigated. The applicability of calculated molecular de-
scriptors, especially the lipophilicity descriptor, ClogP 
and molecular weight (Mw) in CCB elimination 
evaluation was established. The proposed methodol-
ogy confirmed that lipophilicity, together with other 
molecular properties, is essential for drug elimination 
and could assist in the in vitro approach to assessing 
CCB elimination.
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